Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-04-28

AUTHORS

Naoki Hosogaya, Taiga Miyazaki, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Tomoya Kurokawa, Yohei Kawasaki, Michiko Hanawa, Yasuhisa Fujii, Hideki Hanaoka, Shingo Iwami, Koichi Watashi, Satoshi Yamagoe, Yoshitsugu Miyazaki, Takaji Wakita, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae, Shigeru Kohno

ABSTRACT

ObjectivesThe aim of this trial is to evaluate the antiviral efficacy, clinical efficacy, and safety of nelfinavir in patients with asymptomatic and mild COVID-19.Trial designThe study is designed as a multicenter, open-label, blinded outcome assessment, parallel group, investigator-initiated, exploratory, randomized (1:1 ratio) controlled clinical trial.ParticipantsAsymptomatic and mild COVID-19 patients will be enrolled in 10 university and teaching hospitals in Japan. The inclusion and exclusion criteria are as follows:Inclusion criteria: Japanese male or female patients aged ≥ 20 yearsSARS-CoV-2 detected from a respiratory tract specimen (e.g., nasopharyngeal swab or saliva) using PCR, LAMP, or an antigen test within 3 days before obtaining the informed consentProvide informed consentExclusion criteria: Symptoms developed ≥ 8 days prior to enrolmentSpO2 < 96 % (room air)Any of the following screening criteria:ALT or AST ≥ 5 × upper limit of the reference rangeChild-Pugh class B or CSerum creatinine ≥ 2 × upper limit of the reference range and creatinine clearance < 30 mL/minPoorly controlled diabetes (random blood glucose ≥ 200 mg/dL or HbA1c ≥ 7.0%, despite treatment)Unsuitable serious complications based on the assessment of either the principal investigator or the sub-investigatorHemophiliac or patients with a marked hemorrhagic tendencySevere diarrheaHypersensitivity to the investigational drugBreastfeeding or pregnancyWith childbearing potential and rejecting contraceptive methods during the study period from the initial administration of the investigational drugReceiving rifampicin within the previous 2 weeksParticipated in other clinical trials and received drugs within the previous 12 weeksUndergoing treatment for HIV infectionHistory of SARS-CoV-2 vaccination or wishes to be vaccinated against SARS-CoV-2Deemed inappropriate (for miscellaneous reasons) based on the assessment of either the principal investigator or the sub-investigatorIntervention and comparatorPatients who meet the inclusion criteria and do not meet any of the exclusion criteria will be randomized to either the nelfinavir group or the symptomatic treatment group.The nelfinavir group will be administered 750 mg of nelfinavir orally, three times daily for 14 days (treatment period). However, if a participant tests negative on two consecutive PCR tests of saliva samples, administration of the investigational drug for that participant can be discontinued at the discretion of the investigators.The symptomatic treatment group will not be administered the investigational drug, but all other study procedures and conditions will be the same for both groups for the duration of the treatment period. After the treatment period of 14 days, each group will be followed up for 14 days (observational period).Main outcomesThe primary endpoint is the time to negative conversion of SARS-CoV-2. During the study period from Day 1 to Day 28, two consecutive negative PCR results of saliva samples will be considered as the negative conversion of the virus.The secondary efficacy endpoints are as follows:For patients with both asymptomatic and mild disease: area under the curve of viral load, half decay period of viral load, body temperature at each time point, all-cause mortality, incidence rate of pneumonia, percentage of patients with newly developed pneumonia, rate of oxygen administration, and the percentage of patients who require oxygen administration.For asymptomatic patients: incidence of symptomatic COVID-19, incidence of fever (≥ 37.0 °C for two consecutive days), incidence of coughFor patients with mild disease: incidence of defervescence (< 37.0 °C), incidence of recovery from clinical symptoms, incidence of improvement of each symptomThe secondary safety endpoints are adverse events and clinical examinations.RandomizationPatients will be randomized to either the nelfinavir group or the symptomatic treatment group using the electric data capture system (1:1 ratio, dynamic allocation based on severity [asymptomatic], and age [< 60 years]).Blinding (masking)Only the assessors of the primary outcome will be blinded (blinded outcome assessment).Numbers to be randomized (sample size)The sample size was determined based on our power analysis to reject the null hypothesis, S (t | z =1) = S (t | z = 0) where S is a survival function, t is time to negative conversion, and z denotes randomization group, by the log-rank test with a two-sided p value of 0.05. We estimated viral dynamic parameters by fitting a nonlinear mixed-effects model to reported viral load data, and simulated our primary endpoint from viral-load time-courses that were realized from sets of viral dynamics parameters sampled from the estimated probability distribution of the parameters (sample size: 2000; 1000 each for randomization group). From this estimation of the hazard ratio between the randomization groups for the event of negative conversion using this simulation dataset, the required number of events for rejecting our null hypothesis with a power of 0.80 felled 97.345 by plugging the estimated hazard ratio, 1.79, in Freedman’s equation. Therefore, we decided the required number of randomizations to be 120 after consideration of the frequency of censoring and the anticipated rate of withdrawal caused by factors such as withdrawal of consent.Trial StatusProtocol version 6.0 of February 12, 2021. Recruitment started on July 22, 2020 and is anticipated to be completed by March 31, 2022.Trial registrationThis trial was registered in Japan Registry of Clinical Trials (jRCT) (jRCT2071200023) on 21 July 21, 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). More... »

PAGES

309

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-021-05282-w

DOI

http://dx.doi.org/10.1186/s13063-021-05282-w

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1137530229

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33910617


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19 Vaccines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nelfinavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pregnancy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411873.8", 
          "name": [
            "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan", 
            "Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hosogaya", 
        "givenName": "Naoki", 
        "id": "sg:person.0733066377.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733066377.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.174567.6", 
          "name": [
            "Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan", 
            "Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyazaki", 
        "givenName": "Taiga", 
        "id": "sg:person.010263644672.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010263644672.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hospital Pharmacy Nagasaki University Hospital, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411873.8", 
          "name": [
            "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan", 
            "Department of Hospital Pharmacy Nagasaki University Hospital, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fukushige", 
        "givenName": "Yuri", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411873.8", 
          "name": [
            "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takemori", 
        "givenName": "Sachiko", 
        "id": "sg:person.015362655767.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015362655767.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411873.8", 
          "name": [
            "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Shinpei", 
        "id": "sg:person.010727017637.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010727017637.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411873.8", 
          "name": [
            "Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Hiroshi", 
        "id": "sg:person.07746044265.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07746044265.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Chiba University Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Clinical Research Center, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hori", 
        "givenName": "Makoto", 
        "id": "sg:person.010554342311.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010554342311.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Chiba University Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Clinical Research Center, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kurokawa", 
        "givenName": "Tomoya", 
        "id": "sg:person.016156703143.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016156703143.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Chiba University Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Clinical Research Center, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawasaki", 
        "givenName": "Yohei", 
        "id": "sg:person.01340003061.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340003061.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Chiba University Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Clinical Research Center, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanawa", 
        "givenName": "Michiko", 
        "id": "sg:person.015574312112.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015574312112.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Chiba University Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Clinical Research Center, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujii", 
        "givenName": "Yasuhisa", 
        "id": "sg:person.014072055101.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014072055101.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Center, Chiba University Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411321.4", 
          "name": [
            "Clinical Research Center, Chiba University Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanaoka", 
        "givenName": "Hideki", 
        "id": "sg:person.01260546024.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260546024.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.177174.3", 
          "name": [
            "Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwami", 
        "givenName": "Shingo", 
        "id": "sg:person.01051033261.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051033261.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410795.e", 
          "name": [
            "Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan", 
            "Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watashi", 
        "givenName": "Koichi", 
        "id": "sg:person.01263724267.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263724267.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410795.e", 
          "name": [
            "Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamagoe", 
        "givenName": "Satoshi", 
        "id": "sg:person.0746074453.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746074453.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410795.e", 
          "name": [
            "Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyazaki", 
        "givenName": "Yoshitsugu", 
        "id": "sg:person.010674465162.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010674465162.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410795.e", 
          "name": [
            "Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakita", 
        "givenName": "Takaji", 
        "id": "sg:person.0671521055.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671521055.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.174567.6", 
          "name": [
            "Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Izumikawa", 
        "givenName": "Koichi", 
        "id": "sg:person.01225134105.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225134105.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411873.8", 
          "name": [
            "Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yanagihara", 
        "givenName": "Katsunori", 
        "id": "sg:person.01263433603.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263433603.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.174567.6", 
          "name": [
            "Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan", 
            "Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukae", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01143125277.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143125277.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411873.8", 
          "name": [
            "Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kohno", 
        "givenName": "Shigeru", 
        "id": "sg:person.01311530576.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311530576.67"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2021-04-28", 
    "datePublishedReg": "2021-04-28", 
    "description": "ObjectivesThe aim of this trial is to evaluate the antiviral efficacy, clinical efficacy, and safety of nelfinavir in patients with asymptomatic and mild COVID-19.Trial designThe study is designed as a multicenter, open-label, blinded outcome assessment, parallel group, investigator-initiated, exploratory, randomized (1:1 ratio) controlled clinical trial.ParticipantsAsymptomatic and mild COVID-19 patients will be enrolled in 10 university and teaching hospitals in Japan. The inclusion and exclusion criteria are as follows:Inclusion criteria:\nJapanese male or female patients aged \u2265 20 yearsSARS-CoV-2 detected from a respiratory tract specimen (e.g., nasopharyngeal swab or saliva) using PCR, LAMP, or an antigen test within 3 days before obtaining the informed consentProvide informed consentExclusion criteria:\nSymptoms developed \u2265 8 days prior to enrolmentSpO2 < 96 % (room air)Any of the following screening criteria:ALT or AST \u2265 5 \u00d7 upper limit of the reference rangeChild-Pugh class B or CSerum creatinine \u2265 2 \u00d7 upper limit of the reference range and creatinine clearance < 30 mL/minPoorly controlled diabetes (random blood glucose \u2265 200 mg/dL or HbA1c \u2265 7.0%, despite treatment)Unsuitable serious complications based on the assessment of either the principal investigator or the sub-investigatorHemophiliac or patients with a marked hemorrhagic tendencySevere diarrheaHypersensitivity to the investigational drugBreastfeeding or pregnancyWith childbearing potential and rejecting contraceptive methods during the study period from the initial administration of the investigational drugReceiving rifampicin within the previous 2 weeksParticipated in other clinical trials and received drugs within the previous 12 weeksUndergoing treatment for HIV infectionHistory of SARS-CoV-2 vaccination or wishes to be vaccinated against SARS-CoV-2Deemed inappropriate (for miscellaneous reasons) based on the assessment of either the principal investigator or the sub-investigatorIntervention and comparatorPatients who meet the inclusion criteria and do not meet any of the exclusion criteria will be randomized to either the nelfinavir group or the symptomatic treatment group.The nelfinavir group will be administered 750 mg of nelfinavir orally, three times daily for 14 days (treatment period). However, if a participant tests negative on two consecutive PCR tests of saliva samples, administration of the investigational drug for that participant can be discontinued at the discretion of the investigators.The symptomatic treatment group will not be administered the investigational drug, but all other study procedures and conditions will be the same for both groups for the duration of the treatment period. After the treatment period of 14 days, each group will be followed up for 14 days (observational period).Main outcomesThe primary endpoint is the time to negative conversion of SARS-CoV-2. During the study period from Day 1 to Day 28, two consecutive negative PCR results of saliva samples will be considered as the negative conversion of the virus.The secondary efficacy endpoints are as follows:For patients with both asymptomatic and mild disease: area under the curve of viral load, half decay period of viral load, body temperature at each time point, all-cause mortality, incidence rate of pneumonia, percentage of patients with newly developed pneumonia, rate of oxygen administration, and the percentage of patients who require oxygen administration.For asymptomatic patients: incidence of symptomatic COVID-19, incidence of fever (\u2265 37.0 \u00b0C for two consecutive days), incidence of coughFor patients with mild disease: incidence of defervescence (< 37.0 \u00b0C), incidence of recovery from clinical symptoms, incidence of improvement of each symptomThe secondary safety endpoints are adverse events and clinical examinations.RandomizationPatients will be randomized to either the nelfinavir group or the symptomatic treatment group using the electric data capture system (1:1 ratio, dynamic allocation based on severity [asymptomatic], and age [< 60 years]).Blinding (masking)Only the assessors of the primary outcome will be blinded (blinded outcome assessment).Numbers to be randomized (sample size)The sample size was determined based on our power analysis to reject the null hypothesis, S (t | z =1) = S (t | z = 0) where S is a survival function, t is time to negative conversion, and z denotes randomization group, by the log-rank test with a two-sided p value of 0.05. We estimated viral dynamic parameters by fitting a nonlinear mixed-effects model to reported viral load data, and simulated our primary endpoint from viral-load time-courses that were realized from sets of viral dynamics parameters sampled from the estimated probability distribution of the parameters (sample size: 2000; 1000 each for randomization group). From this estimation of the hazard ratio between the randomization groups for the event of negative conversion using this simulation dataset, the required number of events for rejecting our null hypothesis with a power of 0.80 felled 97.345 by plugging the estimated hazard ratio, 1.79, in Freedman\u2019s equation. Therefore, we decided the required number of randomizations to be 120 after consideration of the frequency of censoring and the anticipated rate of withdrawal caused by factors such as withdrawal of consent.Trial StatusProtocol version 6.0 of February 12, 2021. Recruitment started on July 22, 2020 and is anticipated to be completed by March 31, 2022.Trial registrationThis trial was registered in Japan Registry of Clinical Trials (jRCT) (jRCT2071200023) on 21 July 21, 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13063-021-05282-w", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "symptomatic treatment group", 
      "mild COVID-19 patients", 
      "safety of nelfinavir", 
      "percentage of patients", 
      "COVID-19 patients", 
      "nelfinavir group", 
      "negative conversion", 
      "viral dynamic parameters", 
      "clinical trials", 
      "treatment groups", 
      "primary endpoint", 
      "hazard ratio", 
      "oxygen administration", 
      "randomization group", 
      "mild disease", 
      "viral load", 
      "study protocol", 
      "treatment period", 
      "inclusion criteria", 
      "exclusion criteria", 
      "investigational drugs", 
      "consecutive negative PCR results", 
      "SARS-CoV-2 vaccination", 
      "saliva samples", 
      "study period", 
      "respiratory tract specimen", 
      "secondary safety endpoint", 
      "Interventional Trials guidelines", 
      "random blood glucose", 
      "secondary efficacy endpoints", 
      "incidence of fever", 
      "blinded outcome assessment", 
      "symptomatic COVID-19", 
      "incidence of improvement", 
      "log-rank test", 
      "withdrawal of consent", 
      "Standard Protocol Items", 
      "two-sided p value", 
      "viral load data", 
      "SARS-CoV-2", 
      "negative PCR results", 
      "principal investigator", 
      "incidence of recovery", 
      "rate of withdrawal", 
      "full protocol", 
      "Japan Registry", 
      "efficacy endpoint", 
      "cause mortality", 
      "asymptomatic patients", 
      "safety endpoint", 
      "creatinine clearance", 
      "adverse events", 
      "serious complications", 
      "primary outcome", 
      "female patients", 
      "clinical efficacy", 
      "clinical symptoms", 
      "Trials website", 
      "antiviral efficacy", 
      "antigen test", 
      "Trials guidelines", 
      "clinical examination", 
      "parallel group", 
      "blood glucose", 
      "incidence rate", 
      "teaching hospital", 
      "initial administration", 
      "Protocol Items", 
      "designThe study", 
      "contraceptive methods", 
      "patients", 
      "day 28", 
      "ObjectivesThe aim", 
      "day 1", 
      "reference range", 
      "outcome assessment", 
      "incidence", 
      "nelfinavir", 
      "study procedures", 
      "trials", 
      "administration", 
      "time points", 
      "PCR test", 
      "endpoint", 
      "mixed effects models", 
      "multicenter", 
      "PCR results", 
      "drugs", 
      "pneumonia", 
      "COVID-19", 
      "efficacy", 
      "body temperature", 
      "p-value", 
      "symptoms", 
      "disease", 
      "nonlinear mixed effects models", 
      "class B", 
      "days", 
      "data capture system", 
      "withdrawal", 
      "group", 
      "investigators", 
      "structured summary", 
      "sample size", 
      "safety", 
      "defervescence", 
      "period", 
      "complications", 
      "assessment", 
      "creatinine", 
      "diabetes", 
      "vaccination", 
      "fever", 
      "criteria", 
      "registry", 
      "hospital", 
      "AST", 
      "mortality", 
      "ALT", 
      "percentage", 
      "protocol", 
      "rifampicin", 
      "clearance", 
      "version 6.0", 
      "test", 
      "outcomes", 
      "virus", 
      "rate", 
      "treatment", 
      "events", 
      "randomization", 
      "consent", 
      "examination", 
      "survival function", 
      "summary", 
      "duration", 
      "glucose", 
      "PCR", 
      "capture system", 
      "guidelines", 
      "participants", 
      "assessors", 
      "aim", 
      "hypothesis", 
      "samples", 
      "upper limit", 
      "recruitment", 
      "dissemination", 
      "number", 
      "time", 
      "factors", 
      "recommendations", 
      "participant tests", 
      "recovery", 
      "study", 
      "null hypothesis", 
      "power analysis", 
      "ratio", 
      "room", 
      "procedure", 
      "improvement", 
      "items", 
      "frequency", 
      "function", 
      "specimen", 
      "key elements", 
      "inclusion", 
      "data", 
      "discretion", 
      "Japan", 
      "potential", 
      "curves", 
      "analysis", 
      "area", 
      "censoring", 
      "results", 
      "parameters", 
      "conversion", 
      "accordance", 
      "files", 
      "University", 
      "load", 
      "values", 
      "websites", 
      "consideration", 
      "additional files", 
      "conditions", 
      "size", 
      "method", 
      "point", 
      "model", 
      "interest", 
      "materials", 
      "dynamic parameters", 
      "required number", 
      "system", 
      "range", 
      "limit", 
      "distribution", 
      "formatting", 
      "lamp", 
      "letter", 
      "elements", 
      "dataset", 
      "load data", 
      "estimation", 
      "set", 
      "decay period", 
      "power", 
      "temperature", 
      "equations", 
      "probability distribution", 
      "simulation datasets", 
      "half-decay period"
    ], 
    "name": "Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial", 
    "pagination": "309", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1137530229"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-021-05282-w"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33910617"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-021-05282-w", 
      "https://app.dimensions.ai/details/publication/pub.1137530229"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_923.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13063-021-05282-w"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-021-05282-w'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-021-05282-w'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-021-05282-w'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-021-05282-w'


 

This table displays all metadata directly associated to this object as RDF triples.

495 TRIPLES      20 PREDICATES      253 URIs      245 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-021-05282-w schema:about N08c31bbffc8f4f6888d23377c6702643
2 N11ac3d0b3a904ac6b24966145b8212bc
3 N1d67d74af65346009e38fe7539cac42a
4 N3a6bab46c2fe4034ac11818d4eb3163e
5 N4ae5d33af49a4780bdb0a2ed9330955f
6 N6262e9ad96a748ed851277f1f695fdd3
7 N84c12862862f4b1a9b006a8da451005d
8 N861a06ed76fc4ed8a2f69251fe6fcb06
9 N908b7bf5651944d5ad15555027b204c7
10 N9b93d3a94ded4a078a3f9493d518f344
11 Na2905ace93cc4b65b62cc9b4edfca3c6
12 Naea31d3170884d3f90f559b3bab102a6
13 Nc7e9547fecdc4acb99e8f7741ebfa57e
14 Nde55d05b59fd488892cbf9eb38610f93
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nf1eeb1a57b7f4d699edd8e414c943e2c
18 schema:datePublished 2021-04-28
19 schema:datePublishedReg 2021-04-28
20 schema:description ObjectivesThe aim of this trial is to evaluate the antiviral efficacy, clinical efficacy, and safety of nelfinavir in patients with asymptomatic and mild COVID-19.Trial designThe study is designed as a multicenter, open-label, blinded outcome assessment, parallel group, investigator-initiated, exploratory, randomized (1:1 ratio) controlled clinical trial.ParticipantsAsymptomatic and mild COVID-19 patients will be enrolled in 10 university and teaching hospitals in Japan. The inclusion and exclusion criteria are as follows:Inclusion criteria: Japanese male or female patients aged ≥ 20 yearsSARS-CoV-2 detected from a respiratory tract specimen (e.g., nasopharyngeal swab or saliva) using PCR, LAMP, or an antigen test within 3 days before obtaining the informed consentProvide informed consentExclusion criteria: Symptoms developed ≥ 8 days prior to enrolmentSpO2 < 96 % (room air)Any of the following screening criteria:ALT or AST ≥ 5 × upper limit of the reference rangeChild-Pugh class B or CSerum creatinine ≥ 2 × upper limit of the reference range and creatinine clearance < 30 mL/minPoorly controlled diabetes (random blood glucose ≥ 200 mg/dL or HbA1c ≥ 7.0%, despite treatment)Unsuitable serious complications based on the assessment of either the principal investigator or the sub-investigatorHemophiliac or patients with a marked hemorrhagic tendencySevere diarrheaHypersensitivity to the investigational drugBreastfeeding or pregnancyWith childbearing potential and rejecting contraceptive methods during the study period from the initial administration of the investigational drugReceiving rifampicin within the previous 2 weeksParticipated in other clinical trials and received drugs within the previous 12 weeksUndergoing treatment for HIV infectionHistory of SARS-CoV-2 vaccination or wishes to be vaccinated against SARS-CoV-2Deemed inappropriate (for miscellaneous reasons) based on the assessment of either the principal investigator or the sub-investigatorIntervention and comparatorPatients who meet the inclusion criteria and do not meet any of the exclusion criteria will be randomized to either the nelfinavir group or the symptomatic treatment group.The nelfinavir group will be administered 750 mg of nelfinavir orally, three times daily for 14 days (treatment period). However, if a participant tests negative on two consecutive PCR tests of saliva samples, administration of the investigational drug for that participant can be discontinued at the discretion of the investigators.The symptomatic treatment group will not be administered the investigational drug, but all other study procedures and conditions will be the same for both groups for the duration of the treatment period. After the treatment period of 14 days, each group will be followed up for 14 days (observational period).Main outcomesThe primary endpoint is the time to negative conversion of SARS-CoV-2. During the study period from Day 1 to Day 28, two consecutive negative PCR results of saliva samples will be considered as the negative conversion of the virus.The secondary efficacy endpoints are as follows:For patients with both asymptomatic and mild disease: area under the curve of viral load, half decay period of viral load, body temperature at each time point, all-cause mortality, incidence rate of pneumonia, percentage of patients with newly developed pneumonia, rate of oxygen administration, and the percentage of patients who require oxygen administration.For asymptomatic patients: incidence of symptomatic COVID-19, incidence of fever (≥ 37.0 °C for two consecutive days), incidence of coughFor patients with mild disease: incidence of defervescence (< 37.0 °C), incidence of recovery from clinical symptoms, incidence of improvement of each symptomThe secondary safety endpoints are adverse events and clinical examinations.RandomizationPatients will be randomized to either the nelfinavir group or the symptomatic treatment group using the electric data capture system (1:1 ratio, dynamic allocation based on severity [asymptomatic], and age [< 60 years]).Blinding (masking)Only the assessors of the primary outcome will be blinded (blinded outcome assessment).Numbers to be randomized (sample size)The sample size was determined based on our power analysis to reject the null hypothesis, S (t | z =1) = S (t | z = 0) where S is a survival function, t is time to negative conversion, and z denotes randomization group, by the log-rank test with a two-sided p value of 0.05. We estimated viral dynamic parameters by fitting a nonlinear mixed-effects model to reported viral load data, and simulated our primary endpoint from viral-load time-courses that were realized from sets of viral dynamics parameters sampled from the estimated probability distribution of the parameters (sample size: 2000; 1000 each for randomization group). From this estimation of the hazard ratio between the randomization groups for the event of negative conversion using this simulation dataset, the required number of events for rejecting our null hypothesis with a power of 0.80 felled 97.345 by plugging the estimated hazard ratio, 1.79, in Freedman’s equation. Therefore, we decided the required number of randomizations to be 120 after consideration of the frequency of censoring and the anticipated rate of withdrawal caused by factors such as withdrawal of consent.Trial StatusProtocol version 6.0 of February 12, 2021. Recruitment started on July 22, 2020 and is anticipated to be completed by March 31, 2022.Trial registrationThis trial was registered in Japan Registry of Clinical Trials (jRCT) (jRCT2071200023) on 21 July 21, 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
21 schema:genre article
22 schema:isAccessibleForFree true
23 schema:isPartOf N32e3c774705e43ffa154169c65db3c57
24 N77efbd52724e42ffa3ba3b54f6382f86
25 sg:journal.1297400
26 schema:keywords ALT
27 AST
28 COVID-19
29 COVID-19 patients
30 Interventional Trials guidelines
31 Japan
32 Japan Registry
33 ObjectivesThe aim
34 PCR
35 PCR results
36 PCR test
37 Protocol Items
38 SARS-CoV-2
39 SARS-CoV-2 vaccination
40 Standard Protocol Items
41 Trials guidelines
42 Trials website
43 University
44 accordance
45 additional files
46 administration
47 adverse events
48 aim
49 analysis
50 antigen test
51 antiviral efficacy
52 area
53 assessment
54 assessors
55 asymptomatic patients
56 blinded outcome assessment
57 blood glucose
58 body temperature
59 capture system
60 cause mortality
61 censoring
62 class B
63 clearance
64 clinical efficacy
65 clinical examination
66 clinical symptoms
67 clinical trials
68 complications
69 conditions
70 consecutive negative PCR results
71 consent
72 consideration
73 contraceptive methods
74 conversion
75 creatinine
76 creatinine clearance
77 criteria
78 curves
79 data
80 data capture system
81 dataset
82 day 1
83 day 28
84 days
85 decay period
86 defervescence
87 designThe study
88 diabetes
89 discretion
90 disease
91 dissemination
92 distribution
93 drugs
94 duration
95 dynamic parameters
96 efficacy
97 efficacy endpoint
98 elements
99 endpoint
100 equations
101 estimation
102 events
103 examination
104 exclusion criteria
105 factors
106 female patients
107 fever
108 files
109 formatting
110 frequency
111 full protocol
112 function
113 glucose
114 group
115 guidelines
116 half-decay period
117 hazard ratio
118 hospital
119 hypothesis
120 improvement
121 incidence
122 incidence of fever
123 incidence of improvement
124 incidence of recovery
125 incidence rate
126 inclusion
127 inclusion criteria
128 initial administration
129 interest
130 investigational drugs
131 investigators
132 items
133 key elements
134 lamp
135 letter
136 limit
137 load
138 load data
139 log-rank test
140 materials
141 method
142 mild COVID-19 patients
143 mild disease
144 mixed effects models
145 model
146 mortality
147 multicenter
148 negative PCR results
149 negative conversion
150 nelfinavir
151 nelfinavir group
152 nonlinear mixed effects models
153 null hypothesis
154 number
155 outcome assessment
156 outcomes
157 oxygen administration
158 p-value
159 parallel group
160 parameters
161 participant tests
162 participants
163 patients
164 percentage
165 percentage of patients
166 period
167 pneumonia
168 point
169 potential
170 power
171 power analysis
172 primary endpoint
173 primary outcome
174 principal investigator
175 probability distribution
176 procedure
177 protocol
178 random blood glucose
179 randomization
180 randomization group
181 range
182 rate
183 rate of withdrawal
184 ratio
185 recommendations
186 recovery
187 recruitment
188 reference range
189 registry
190 required number
191 respiratory tract specimen
192 results
193 rifampicin
194 room
195 safety
196 safety endpoint
197 safety of nelfinavir
198 saliva samples
199 sample size
200 samples
201 secondary efficacy endpoints
202 secondary safety endpoint
203 serious complications
204 set
205 simulation datasets
206 size
207 specimen
208 structured summary
209 study
210 study period
211 study procedures
212 study protocol
213 summary
214 survival function
215 symptomatic COVID-19
216 symptomatic treatment group
217 symptoms
218 system
219 teaching hospital
220 temperature
221 test
222 time
223 time points
224 treatment
225 treatment groups
226 treatment period
227 trials
228 two-sided p value
229 upper limit
230 vaccination
231 values
232 version 6.0
233 viral dynamic parameters
234 viral load
235 viral load data
236 virus
237 websites
238 withdrawal
239 withdrawal of consent
240 schema:name Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial
241 schema:pagination 309
242 schema:productId N38cec831cee446ba962ab051157d8e89
243 N7d13e7705fd343d1a8cc01a092c1faf5
244 Nf5ff560b043540a7b1454f554463ecb7
245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137530229
246 https://doi.org/10.1186/s13063-021-05282-w
247 schema:sdDatePublished 2022-09-02T16:07
248 schema:sdLicense https://scigraph.springernature.com/explorer/license/
249 schema:sdPublisher N5e0d975a42654cb4bad125d9b21d432f
250 schema:url https://doi.org/10.1186/s13063-021-05282-w
251 sgo:license sg:explorer/license/
252 sgo:sdDataset articles
253 rdf:type schema:ScholarlyArticle
254 N03c04ad8e7544f3fa230143b2d7ad486 rdf:first sg:person.010727017637.05
255 rdf:rest N291495560829472daa9b4572ffcb004e
256 N08c31bbffc8f4f6888d23377c6702643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
257 schema:name Nelfinavir
258 rdf:type schema:DefinedTerm
259 N0a5b59a1102e4a7b8e21b3f089b4ea94 rdf:first sg:person.015574312112.21
260 rdf:rest Ndc0c0cee6a7440eea9cdcf72a1a111f9
261 N11ac3d0b3a904ac6b24966145b8212bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
262 schema:name COVID-19
263 rdf:type schema:DefinedTerm
264 N1d67d74af65346009e38fe7539cac42a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
265 schema:name Humans
266 rdf:type schema:DefinedTerm
267 N291495560829472daa9b4572ffcb004e rdf:first sg:person.07746044265.25
268 rdf:rest N8900991fbeaf4b2a998e99f992ca327b
269 N2b4c40b2bb2e418292279dffe25a4ba7 rdf:first sg:person.0671521055.46
270 rdf:rest N30536c2652074ec294ae0d2e88d758d8
271 N30536c2652074ec294ae0d2e88d758d8 rdf:first sg:person.01225134105.22
272 rdf:rest N35004e9c87374ac78154221244389692
273 N32e3c774705e43ffa154169c65db3c57 schema:issueNumber 1
274 rdf:type schema:PublicationIssue
275 N35004e9c87374ac78154221244389692 rdf:first sg:person.01263433603.25
276 rdf:rest N8a6ad4a400664e2a8574f48ae3076c6b
277 N38cec831cee446ba962ab051157d8e89 schema:name doi
278 schema:value 10.1186/s13063-021-05282-w
279 rdf:type schema:PropertyValue
280 N3a6bab46c2fe4034ac11818d4eb3163e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
281 schema:name Male
282 rdf:type schema:DefinedTerm
283 N4ae5d33af49a4780bdb0a2ed9330955f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
284 schema:name Japan
285 rdf:type schema:DefinedTerm
286 N5bb7d95e2f7c406c9934fac838739f1d rdf:first sg:person.016156703143.75
287 rdf:rest N701bf21c1942419e99215bd4a048b141
288 N5e0d975a42654cb4bad125d9b21d432f schema:name Springer Nature - SN SciGraph project
289 rdf:type schema:Organization
290 N5ec12e8715f2462581ddd7e9f56abe29 rdf:first sg:person.010674465162.24
291 rdf:rest N2b4c40b2bb2e418292279dffe25a4ba7
292 N6262e9ad96a748ed851277f1f695fdd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
293 schema:name Middle Aged
294 rdf:type schema:DefinedTerm
295 N701bf21c1942419e99215bd4a048b141 rdf:first sg:person.01340003061.54
296 rdf:rest N0a5b59a1102e4a7b8e21b3f089b4ea94
297 N77efbd52724e42ffa3ba3b54f6382f86 schema:volumeNumber 22
298 rdf:type schema:PublicationVolume
299 N7d13e7705fd343d1a8cc01a092c1faf5 schema:name pubmed_id
300 schema:value 33910617
301 rdf:type schema:PropertyValue
302 N7f65f5978a35485585a5047906dc2374 rdf:first Ned1eb6b613614b43be7cec60194897a2
303 rdf:rest Nd110a2c5892945bdab308387abc69adf
304 N7f71ce2d58d14c3b86b6728a351a6b59 rdf:first sg:person.0746074453.13
305 rdf:rest N5ec12e8715f2462581ddd7e9f56abe29
306 N84c12862862f4b1a9b006a8da451005d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
307 schema:name Randomized Controlled Trials as Topic
308 rdf:type schema:DefinedTerm
309 N861a06ed76fc4ed8a2f69251fe6fcb06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
310 schema:name Multicenter Studies as Topic
311 rdf:type schema:DefinedTerm
312 N87d780ee7855431da5591334afac3748 rdf:first sg:person.010263644672.01
313 rdf:rest N7f65f5978a35485585a5047906dc2374
314 N8900991fbeaf4b2a998e99f992ca327b rdf:first sg:person.010554342311.08
315 rdf:rest N5bb7d95e2f7c406c9934fac838739f1d
316 N8a6ad4a400664e2a8574f48ae3076c6b rdf:first sg:person.01143125277.28
317 rdf:rest Nac3d76c2570747dea4b2e9f1ed24862e
318 N908b7bf5651944d5ad15555027b204c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
319 schema:name COVID-19 Vaccines
320 rdf:type schema:DefinedTerm
321 N9b93d3a94ded4a078a3f9493d518f344 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
322 schema:name SARS-CoV-2
323 rdf:type schema:DefinedTerm
324 Na272454e64fb44e69e61552d01f0bea6 rdf:first sg:person.01260546024.15
325 rdf:rest Nfc89f1204e024923b79558518098ede8
326 Na2905ace93cc4b65b62cc9b4edfca3c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
327 schema:name HIV Infections
328 rdf:type schema:DefinedTerm
329 Nac3d76c2570747dea4b2e9f1ed24862e rdf:first sg:person.01311530576.67
330 rdf:rest rdf:nil
331 Naea31d3170884d3f90f559b3bab102a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
332 schema:name Pregnancy
333 rdf:type schema:DefinedTerm
334 Nc7e9547fecdc4acb99e8f7741ebfa57e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
335 schema:name Treatment Outcome
336 rdf:type schema:DefinedTerm
337 Nd110a2c5892945bdab308387abc69adf rdf:first sg:person.015362655767.48
338 rdf:rest N03c04ad8e7544f3fa230143b2d7ad486
339 Ndc0c0cee6a7440eea9cdcf72a1a111f9 rdf:first sg:person.014072055101.64
340 rdf:rest Na272454e64fb44e69e61552d01f0bea6
341 Nde55d05b59fd488892cbf9eb38610f93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
342 schema:name Female
343 rdf:type schema:DefinedTerm
344 Neb92b75f68a24e1993bbc360d2d3c2b1 rdf:first sg:person.01263724267.41
345 rdf:rest N7f71ce2d58d14c3b86b6728a351a6b59
346 Ned1eb6b613614b43be7cec60194897a2 schema:affiliation grid-institutes:grid.411873.8
347 schema:familyName Fukushige
348 schema:givenName Yuri
349 rdf:type schema:Person
350 Nf1eeb1a57b7f4d699edd8e414c943e2c rdf:first sg:person.0733066377.41
351 rdf:rest N87d780ee7855431da5591334afac3748
352 Nf5ff560b043540a7b1454f554463ecb7 schema:name dimensions_id
353 schema:value pub.1137530229
354 rdf:type schema:PropertyValue
355 Nfc89f1204e024923b79558518098ede8 rdf:first sg:person.01051033261.50
356 rdf:rest Neb92b75f68a24e1993bbc360d2d3c2b1
357 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
358 schema:name Medical and Health Sciences
359 rdf:type schema:DefinedTerm
360 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
361 schema:name Clinical Sciences
362 rdf:type schema:DefinedTerm
363 sg:journal.1297400 schema:issn 1468-6708
364 1745-6215
365 schema:name Trials
366 schema:publisher Springer Nature
367 rdf:type schema:Periodical
368 sg:person.010263644672.01 schema:affiliation grid-institutes:grid.174567.6
369 schema:familyName Miyazaki
370 schema:givenName Taiga
371 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010263644672.01
372 rdf:type schema:Person
373 sg:person.01051033261.50 schema:affiliation grid-institutes:grid.177174.3
374 schema:familyName Iwami
375 schema:givenName Shingo
376 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051033261.50
377 rdf:type schema:Person
378 sg:person.010554342311.08 schema:affiliation grid-institutes:grid.411321.4
379 schema:familyName Hori
380 schema:givenName Makoto
381 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010554342311.08
382 rdf:type schema:Person
383 sg:person.010674465162.24 schema:affiliation grid-institutes:grid.410795.e
384 schema:familyName Miyazaki
385 schema:givenName Yoshitsugu
386 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010674465162.24
387 rdf:type schema:Person
388 sg:person.010727017637.05 schema:affiliation grid-institutes:grid.411873.8
389 schema:familyName Morimoto
390 schema:givenName Shinpei
391 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010727017637.05
392 rdf:type schema:Person
393 sg:person.01143125277.28 schema:affiliation grid-institutes:grid.174567.6
394 schema:familyName Mukae
395 schema:givenName Hiroshi
396 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143125277.28
397 rdf:type schema:Person
398 sg:person.01225134105.22 schema:affiliation grid-institutes:grid.174567.6
399 schema:familyName Izumikawa
400 schema:givenName Koichi
401 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225134105.22
402 rdf:type schema:Person
403 sg:person.01260546024.15 schema:affiliation grid-institutes:grid.411321.4
404 schema:familyName Hanaoka
405 schema:givenName Hideki
406 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260546024.15
407 rdf:type schema:Person
408 sg:person.01263433603.25 schema:affiliation grid-institutes:grid.411873.8
409 schema:familyName Yanagihara
410 schema:givenName Katsunori
411 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263433603.25
412 rdf:type schema:Person
413 sg:person.01263724267.41 schema:affiliation grid-institutes:grid.410795.e
414 schema:familyName Watashi
415 schema:givenName Koichi
416 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263724267.41
417 rdf:type schema:Person
418 sg:person.01311530576.67 schema:affiliation grid-institutes:grid.411873.8
419 schema:familyName Kohno
420 schema:givenName Shigeru
421 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311530576.67
422 rdf:type schema:Person
423 sg:person.01340003061.54 schema:affiliation grid-institutes:grid.411321.4
424 schema:familyName Kawasaki
425 schema:givenName Yohei
426 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340003061.54
427 rdf:type schema:Person
428 sg:person.014072055101.64 schema:affiliation grid-institutes:grid.411321.4
429 schema:familyName Fujii
430 schema:givenName Yasuhisa
431 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014072055101.64
432 rdf:type schema:Person
433 sg:person.015362655767.48 schema:affiliation grid-institutes:grid.411873.8
434 schema:familyName Takemori
435 schema:givenName Sachiko
436 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015362655767.48
437 rdf:type schema:Person
438 sg:person.015574312112.21 schema:affiliation grid-institutes:grid.411321.4
439 schema:familyName Hanawa
440 schema:givenName Michiko
441 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015574312112.21
442 rdf:type schema:Person
443 sg:person.016156703143.75 schema:affiliation grid-institutes:grid.411321.4
444 schema:familyName Kurokawa
445 schema:givenName Tomoya
446 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016156703143.75
447 rdf:type schema:Person
448 sg:person.0671521055.46 schema:affiliation grid-institutes:grid.410795.e
449 schema:familyName Wakita
450 schema:givenName Takaji
451 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671521055.46
452 rdf:type schema:Person
453 sg:person.0733066377.41 schema:affiliation grid-institutes:grid.411873.8
454 schema:familyName Hosogaya
455 schema:givenName Naoki
456 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733066377.41
457 rdf:type schema:Person
458 sg:person.0746074453.13 schema:affiliation grid-institutes:grid.410795.e
459 schema:familyName Yamagoe
460 schema:givenName Satoshi
461 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746074453.13
462 rdf:type schema:Person
463 sg:person.07746044265.25 schema:affiliation grid-institutes:grid.411873.8
464 schema:familyName Yamamoto
465 schema:givenName Hiroshi
466 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07746044265.25
467 rdf:type schema:Person
468 grid-institutes:grid.174567.6 schema:alternateName Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan
469 Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
470 schema:name Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan
471 Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
472 Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
473 rdf:type schema:Organization
474 grid-institutes:grid.177174.3 schema:alternateName Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan
475 schema:name Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan
476 rdf:type schema:Organization
477 grid-institutes:grid.410795.e schema:alternateName Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan
478 Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
479 Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan
480 schema:name Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan
481 Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
482 Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan
483 rdf:type schema:Organization
484 grid-institutes:grid.411321.4 schema:alternateName Clinical Research Center, Chiba University Hospital, Chiba, Japan
485 schema:name Clinical Research Center, Chiba University Hospital, Chiba, Japan
486 rdf:type schema:Organization
487 grid-institutes:grid.411873.8 schema:alternateName Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
488 Department of Hospital Pharmacy Nagasaki University Hospital, Nagasaki, Japan
489 Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
490 Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
491 schema:name Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
492 Department of Hospital Pharmacy Nagasaki University Hospital, Nagasaki, Japan
493 Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
494 Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
495 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...